Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary

Author:

Achtnichts L1,Chan A2,Czaplinski A3,Derfuss T4,Du Pasquier R5,Findling O1,Gobbi C6,Hoepner R2,Kamber N2,Kamm CP27,Kuhle J4,Lalive P8,Lutterotti A9,Martin R9,Müller S10,Papadopoulou A411,Pot C5,Salmen A2,Schippling S912,Zecca C6,

Affiliation:

1. Department of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland

2. Department of Neurology, Bern University Hospital, University of Bern, Bern, Switzerland

3. Neurozentrum Bellevue, Zürich, Switzerland

4. Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland

5. Division of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland

6. Division of Neurology, Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Ospedale Regionale, Lugano, Switzerland

7. Neurology and Neurorehabilitation Center, Lucerne Cantonal Hospital, Lucerne, Switzerland

8. Department of Neurosciences, Division of Neurology, Unit of Neuroimmunology and Neuromuscular Diseases, University Hospital of Geneva, Geneva, Switzerland

9. Neuroimmunology and Multiple Sclerosis Research (nims), Department of Neurology, University Hospital Zurich and University of Zurich, Zürich, Switzerland

10. Department of Neurology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

11. NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

12. Neuroscience Center Zurich, University of Zurich and Federal Institute of Technology (ETH) Zurich, Zürich, Switzerland

Abstract

More than a dozen substances are meanwhile available for the disease-modifying immunotherapy of multiple sclerosis (MS). However, for some substances, there is a clear difference between approval in Switzerland (Swissmedic) and neighboring countries (European Medicines Agency (EMA)). In addition, limitations imposed by the Swiss Federal Office of Public Health in the specialties list (SL) have significant effects on use in daily clinical practice. In the following, we present consensus recommendations, which were reviewed and agreed upon by the Scientific Advisory Board of the Swiss Multiple Sclerosis Society and the Swiss Neurological Society. We explicitly focus on practice-relevant differences in the approval of MS immunotherapies in Switzerland compared with the EMA area and discuss further limitations (SL) and their impact on the use in clinical practice. Immunotherapies with the same approval in Switzerland and the EMA area and symptomatic therapies are not discussed here.

Publisher

MDPI AG

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3